|Bid||144.99 x 200|
|Ask||158.10 x 100|
|Day's Range||143.54 - 146.05|
|52 Week Range||137.17 - 192.15|
|PE Ratio (TTM)||27.40|
|Forward Dividend & Yield||0.92 (0.63%)|
|1y Target Est||213.93|
Directorate Change Dublin, Ireland - January 19, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announces that Thomas Dittrich will assume his role as Chief Financial Officer, and ...
In 3Q17, Bioverativ’s (BIVV) drug Alprolix generated revenue of $88.5 million, which reflected a rise of ~4% on a year-over-year (or YoY) basis. In 3Q17, Alprolix contributed ~32.2% of Bioverativ’s net product sales. Alprolix reported revenue of $264.2 million in the first nine months of 2017 (which ended in September 2017) compared to its revenue of $240.5 million in the first nine months of 2016.
Shire (SHP.L) ditched its revenue target of $20 billion (14.8 billion pounds) by 2020 on Monday due to increased generic competition and new drugs from rivals, saying it would split its rare disease and hyperactivity medicines businesses to boost performance. The London-listed pharmaceutical group said total revenue would now reach $17-18 billion by 2020, dropping the goal set two years ago when it acquired haemophilia specialist Baxalta. Chief Executive Flemming Ornskov, said that revenue had tripled to $15 billion in five years and that $20 billion was a "stretch target".
Rare disease drugmaker Shire cut its 2020 revenue forecast on Monday, and announced that it plans to split its ADHD drugs into a separate division, with a possible spinout in the future. Shire (SHPG), the state’s second largest biopharma employer, said that it is now projecting its total revenue to reach $17 billion to $18 billion by 2020. Shares of Shire were down more than 4 percent as of 11 a.m., shaving nearly $2 billion off its market capitalization, which was around $45 billion before the selloff.
London-listed pharmaceutical group Shire said on Monday it would create two distinct business units for its rare disease and hyperactivity medicines before deciding later this year whether to spin off the latter into a separately listed group. Shire said that following a review it had decided its neuroscience business, which makes the attention deficit hyperactivity disorder (ADHD) blockbuster Vyvanse, warranted additional focus and investment. "Shire has undergone a significant transformation over the last five years creating two market-leading businesses with distinct profiles and future needs," chief executive Flemming Ornskov said.
Shire Announces Business Update at 36 th Annual J.P. Morgan Healthcare Conference Projects continued strong growth as the global leader in rare diseases, led by the immunology franchise Will ...
In 3Q17, Novo Nordisk’s (NVO) hemophilia segment reported revenues of 2.4 billion Danish krone (or DKK), a ~10% increase on a YoY basis.
Mixed results from two late-stage studies testing Kala Pharmaceuticals Inc's drug to provide temporary relief from dry eye disease cast doubt on the drug's path forward and sent shares down 16 percent in early trading on Friday. "The question is will the FDA accept this or make them do another trial before approval?" Wedbush analyst Liana Moussatos told Reuters, dubbing Kala's first trial "the best results" for dry eye she'd seen in a late-stage study.
Shire to present at the 36th Annual J.P. Morgan Healthcare Conference Cambridge, MA - January 4, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) announces that Flemming Ornskov, M.D., M.P.H., Chief Executive ...
Total Voting Rights January 2, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company"), in accordance with 5.6.1R of the Financial Conduct Authority`s (the "FCA") Disclosure Guidance ...
Director Declaration Dublin, Ireland - January 2, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announces that Dominic Blakemore, Non-Executive Director of the Company, was appointed ...
Categories: Yahoo FinanceGet free summary analysis Shire Plc reports financial results for the quarter ended September 30, 2017. Highlights Summary numbers: Revenues of USD 3,720.03 million, Net Earnings of USD 554.54 million. Gross margins widened from 38.31% to 58.52% compared to the same period last year, operating (EBITDA) margins now 42.01% from 12.23%. Change in operating cash ... Read more (Read more...)
Protalix BioTherapeutics's (PLX) pipeline candidate, PRX-102, gets orphan drug status in Europe which is being developed as a treatment for Fabry disease.
Shares of Shire (SHPG) are lower on Wednesday, after the drug maker said it filed its first submission for its new plasma manufacturing facility in Georgia to the Food and Drug Administration. Cantor Fitzgerald's Louise Chen and her team write that the new facility will support Shire's immunology franchise, which has seen sales climb some 21% in 2017, easily above the 6% to 8% growth the company originally expected. SHPG guided to overall gross margins of 74.5%-76.5% in 2017 for the entire business, but did not break this out by business segments.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Shire Plc Here are 5 ETFs with the largest exposure to SHPG-US. Comparing the performance and risk of Shire Plc with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
Shire files for FDA approval of a new plasma manufacturing facility in Covington, Georgia to support growing Immunology franchise Dublin, Ireland - December 27, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG), ...
The most recent earnings update Shire plc’s (LSE:SHP) released in September 2017 indicated that the business experienced a major headwind with earnings deteriorating by -54.88%. Below, I’ve presented key growthRead More...
Shire plc’s (NASDAQ:SHPG) most recent earnings announcement in September 2017 revealed that the business endured a immense headwind with earnings falling by -54.88%. Below, I’ve presented key growth figures onRead More...
Director/PDMR Shareholding December 20, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) Notification of transactions by persons discharging managerial responsibilities 1. Details of the person discharging ...
Shire Plc's experimental treatment for children with Hunter syndrome and cognitive impairment failed to meet the main and secondary goals of a late-stage clinical trial. The trial evaluated the efficacy of Shire's treatment, SHP609, based on changes in cognition between children treated with the drug and those on a placebo, the London-listed drugmaker said on Tuesday. Hunter syndrome is a rare, inherited metabolic disorder that mainly affects males.
The U.S.-listed shares of Shire PLC fell 1.2% in premarket trade Tuesday, after the Ireland-based drug maker said a phase 2/3 trial of its treatment for Hunter syndrome in pediatric patients failed to ...
Shire Plc's investigational drug for treating pediatric patients with Hunter syndrome and cognitive impairment failed to meet the main goal of a late-stage trial. The clinical trial evaluating SHP609, ...